

GENERATION OF PRIMARY CYTOTOXIC LYMPHOCYTES
AGAINST NON-MAJOR HISTOCOMPATIBILITY COMPLEX
ANTIGENS BY ANTI-Ia SERUM
PLUS COMPLEMENT-TREATED LYMPHOCYTES*

BY COLLEEN E. HAYES, STUART MACPHAIL, AND FRITZ H. BACH

*From the Immunobiology Research Center, Departments of Biochemistry, Medical Genetics, and Surgery,
University of Wisconsin, Madison, Wisconsin 53706*

Histocompatibility loci have been classified as major histocompatibility complex (MHC) or minor histocompatibility complex (non-MHC) based on the time-course of *in vivo* graft rejection, the relative ease with which alloantiserum may be produced, and the characteristics of the *in vitro* mixed-leukocyte culture (MLC) (1). Attempts to sensitize cytotoxic lymphocytes (T_c) against minor histocompatibility antigens *in vitro* have failed (2–5). This does not seem to reflect the absence of non-MHC-antigen-recognizing T_c precursor cells; *in vivo* or *in vitro* primed lymphocytes, secondarily challenged *in vitro*, give rise to strong cytotoxic responses (6–8). Because the immunological outcome of antigenic challenge most probably depends upon a balance between positive and negative influences on certain fundamental pathways, we theorized that the failure to induce primary T_c in MHC-identical, non-MHC-disparate strain combinations might be a result of either a suppressive mechanism that impedes T_c development, or the absence of appropriate amplification mechanisms. We sought evidence for this hypothesis by testing cytotoxic responses of anti-Ia serum plus complement-treated lymphocytes cultured *in vitro* with MHC-identical, non-MHC-disparate stimulating cells. We selected this approach on the basis of evidence for differential expression of I-region determinants on regulatory T cells in other systems (9), and the strong reactivity of the antiserum used herein with T lymphocytes (10). Our results demonstrate that the responding cells that remain can mount a highly significant primary, *in vitro* T_c response to non-MHC antigens in several strain combinations.

Materials and Methods

Animals. B10.BR, B10.D2, and B10.S mice were bred in our colony (University of Wisconsin, Madison, Wis.). C3H/HeJ, AKR/J, BALB/c, and CBA/J mice were purchased from The Jackson Laboratory, Bar Harbor, Maine. Male and female animals 6–12 wk of age were used. Guinea pigs were obtained from Mogul Ed., Oshkosh, Wis.

Media. All media and supplements were purchased from Grand Island Biological Co., Grand Island, N. Y. Hanks' balanced salt solution without bicarbonate was supplemented with

* Supported by National Foundation grant 5-192 and National Institutes of Health grants AI 15728, AI 15588, and CA 16836. This is paper 215 from the Immunobiology Research Center and paper 2,413 from the Laboratory of Genetics, University of Wisconsin, Madison, Wis.

0.05 M Hepes buffer (HBSS). Mishell-Dutton medium (11), freshly prepared and supplemented with 5×10^{-5} M 2-mercaptoethanol and 2% heat-inactivated fetal calf serum (FCS) (Flow Laboratories, Inc., Rockville, Md.), was used throughout. Cytotoxicity assays were performed in cell culture medium fortified with 5% FCS.

Antisera. (A.TH \times B10.HTT)F₁ anti-A.TL serum, hereafter termed anti-Ia, was prepared by concanavalin A (Con A) thymocyte blast immunization as described by Hayes and Bach (12). The method of Reif and Allen (13) was used to prepare anti-Thy-1.2 serum. Antisera were tested by a two-stage, dye-exclusion microcytotoxicity test (12). Anti-Ia serum lysed >50% of A.TL lymph node cells, with half-maximal lysis at a 1:1,280 dilution. Anti-Thy-1.2 lysed >95% of C3H/HeJ thymocytes, with half-maximal lysis at a 1:640 dilution. Fresh guinea pig serum, obtained bimonthly by heart puncture, served as complement (C). For anti-Ia serum lysis of splenocytes, cells were suspended in HBSS-diluted antiserum (1.0 ml of 1:20/5 $\times 10^7$ cells) and incubated on ice for 15 min. 10 vol of cold HBSS were added, the cells pelleted (1,000 rpm, 10 min), and resuspended in HBSS-diluted C (1.0 ml of 1:25/5 $\times 10^7$ cells). After 30 min at 37°C, the cells were washed twice with HBSS and resuspended in culture medium. Cultured lymphocytes were lysed with anti-Thy-1.2 serum plus C according to the same protocol, except that serum was diluted 1:15, C was absorbed with mouse spleen cells (5 ml of 1:5-diluted C; 1×10^8 cells; 15 min on ice), and the treatment was repeated one additional time. For absorption experiments, HBSS-diluted anti-Ia serum (1.0 ml of 1:20) was absorbed twice (15 min on ice) with either B10.S or B10.BR splenocytes (1×10^8 cell/absorption).

Cell Counting. Cell viability was determined by trypan blue exclusion staining. Cell concentrations are expressed as viable cells per milliliter.

MLC. Responding splenocytes, either untreated or treated with antiserum and C, were suspended in culture medium and aliquoted into microtiter wells (5×10^5 cell/well) (No. 76-002-05, Linbro Chemical Co., Hamden, Conn.). X-irradiated (2,000 R), stimulating splenocytes, suspended in culture medium, were aliquoted into wells (5×10^5 cell/well). Total cell culture vol was 0.2 ml. In some experiments, 24-well culture plates (No. 76-033-05, Linbro Chemical Co.) were used (5×10^6 cells of each type; 2.0 ml). After 5–6 d at 37°C in a humidified atmosphere of 5% CO₂ in air, replicate cultures were resuspended with a Pasteur pipet, pooled, washed with HBSS, and resuspended in fresh medium with 5% FCS (2.5×10^6 cell/ml) for cytotoxicity assay.

Cell-mediated Lympholysis Assay. Blast cell targets were prepared 48 h beforehand by adding Con A (2.5 μ g/ml; Pharmacia Fine Chemicals, Inc., Uppsala, Sweden) to replicate cultures of splenocytes in medium with 5% FCS (15×10^6 cell/3 ml; 35×10 -mm tissue culture dishes; No. 3001, Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, Calif.). To an aliquot of Con A-stimulated blast cells (5×10^6 cells in 0.3 ml HBSS with 5% FCS) was added Na₂⁵¹CrO₄ (50 μ l of 5 mCi/ml; New England Nuclear, Boston, Mass.), and the mixture was incubated at 37°C for 1 h, resuspending the cells at 15-min intervals. ⁵¹Cr-labeled cells, washed three times with HBSS, were resuspended in medium with 5% FCS at 5×10^4 cell/ml.

⁵¹Cr-release assays were performed in microtiter plates (No. 76-011-05, Linbro Chemical Co.). Appropriately diluted effector cell suspensions (0.1 ml) followed by ⁵¹Cr-labeled target cells (0.1 ml) were dispensed into each of four replicate wells. Six replicate wells of medium and target cells served as background controls; six wells of detergent (0.5% Nonidet P40, Shell Oil Co., Houston, Tex.) and target cells gave maximal ⁵¹Cr-release values. Plates were centrifuged (250 g, 5 min) then incubated for 8 h at 37°C in a humidified atmosphere of CO₂ in air. A 100- μ l sample was removed from each well and counted in a Packard 5320 auto gamma scintillation spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.).

Data Calculation, Presentation, and Statistical Evaluation. Percent specific ⁵¹Cr release was calculated for each replicate sample according to the formula:

$$\text{Percent specific } ^{51}\text{Cr release} = 100 \left[\frac{\text{experimental release (counts per minute)} - \text{background release (counts per minute)}}{\text{maximal release (counts per minute)} - \text{background release (counts per minute)}} \right]$$

The mean value of replicate samples \pm SD is presented.




FIG. 1. (Left) Primary cytotoxic responses are developed in vitro by anti-Ia serum plus C-treated lymphocytes against *H-2*-identical, non-MHC-disparate stimulating cells. Untreated B10.BR cells cultured alone (▲), NMS + C-treated B10.BR cells cultured with X-irradiated CBA cells (○), and anti-Ia + C-treated B10.BR cells cultured with X-irradiated CBA cells (●) were assayed on day 6 for cytotoxic activity on ⁵¹Cr-labeled CBA target cells.

FIG. 2. (Right) Primary cytotoxic responses are developed in vitro by anti-Ia serum plus C-treated lymphocytes against a variety of *H-2*-identical, non-MHC-disparate stimulating (Stim.) strains. Responding (Resp.) cells are either untreated (□), NMS + C treated (■), or anti-Ia serum + C treated (▨). a, effector:target ratio 50:1. b, phytohemagglutinin blast, 4-h assay.

Results

Primary cytotoxic responses are developed in vitro by anti-Ia serum- and C-treated B10.BR (*H-2^k*) lymphocytes against *H-2*-identical, non-MHC-disparate CBA/J (*H-2^k*) stimulating cells (Fig. 1). B10.BR cells, untreated and cultured alone, or pretreated with normal mouse serum (NMS) and C and cultured with X-irradiated CBA/J stimulating cells, do not show significant cytotoxicity against ⁵¹Cr-labeled CBA blasts after 6 d in culture. No autokilling of B10.BR targets was observed.

The ability to generate cytotoxicity to non-MHC antigens in a primary MLC, if the responding cells are first treated with anti-Ia serum and C, can be demonstrated in several different strain combinations (Fig. 2). In each experiment, cytotoxicity on the relevant target cell is compared for untreated, unstimulated cells; NMS and C-treated cells stimulated with X-irradiated, non-MHC-disparate cells; and anti-Ia serum and C-treated cells stimulated with X-irradiated non-MHC-disparate cells. Three combinations are shown that represent two different responding strains and two different sensitizing strains. In each case, significant cell-mediated lysis was observed only in the anti-Ia serum plus C-treated group. Lysis appeared to be antigen specific in that target cells of other strains were not lysed (C3H primed with CBA_x did not lyse B10.D2 or AKR targets; B10.BR primed with AKR did not lyse CBA targets; B10.BR primed with CBA did not lyse AKR targets [data not shown]). In some instances, cross-reactivity was observed. For example, CBA-primed B10.BR cells lysed CBA (40.1 ± 11.1%) and to a lesser extent BALB/c targets (13.0 ± 9.6%) in one experiment, and CBA (67.0 ± 9.6%) and C3H targets (48.6 ± 5.2%) in a second experiment.

The cytotoxic cells that develop upon culture of anti-Ia serum plus C-treated B10.BR responding lymphocytes with CBA stimulating cells bear the Thy-1.2 antigen. In vitro primed cytotoxic effector cells, derived from cultures of anti-Ia serum and C-treated responding cells, were tested for their susceptibility to anti-Thy-1.2 serum and C lysis immediately before the cell-mediated lympholysis assay: untreated cytotoxic cells lysed CBA targets ($22.6 \pm 4.9\%$) as did NMS and C-treated cells ($20.5 \pm 4.9\%$). Two-cycle anti-Thy-1.2 plus C treatment virtually eliminated cytotoxicity ($3.4 \pm 3.1\%$). Thus, the cytotoxic effector cells appear to be T cells.

The anti-Ia serum used in these experiments has been extensively characterized with regard to its haplotype specificity (10). Absorption results confirmed this specificity: B10.BR cells that remained after treatment with unabsorbed anti-Ia serum and C lysed CBA targets ($29.0 \pm 8.7\%$) after being cultured 6 d in vitro with CBA stimulating cells. When anti-Ia serum was first absorbed with B10.BR or C3H spleen cells, T_c did not develop ($-8.7 \pm 7.3\%$). On the other hand, anti-Ia serum retained its reactivity after absorption with B10.S spleen cells ($28.0 \pm 11.1\%$).

Discussion

The results presented in this paper demonstrate that responding cells that remain after anti-Ia serum and C treatment generate a highly significant cytotoxic response against non-MHC antigens: NMS and C-treated control cells do not. The cytotoxic response appears to be antigen specific in that target cells of strains other than the sensitizing strain are not lysed, or lysed to a lesser extent. The cytotoxic cells are susceptible to anti-Thy-1.2 and C lysis. Thus, they appear to be T_c.

The anti-Ia serum employed in these studies has been well characterized with respect to its specificity (10). It contains antibody to both I-A^k- and I-J^k-encoded antigens; I-B^k, Qa, and Tla activity were not observed (10). Experiments are in progress to determine which antiserum component(s) are necessary to bring about non-MHC-T_c induction.

Since the advent of transplantation, immunogeneticists have questioned the basis of phenomenological distinctions between major and minor transplantation antigens. One hypothesis to explain some characteristic immunological differences between these antigens suggests that T_c development is subject to suppressive and enhancing regulatory influences; strong and weak antigens might then differ primarily in the overall balance between such regulatory mechanisms that they elicit and, therefore, in their ability to induce T_c. The results presented here can be interpreted in view of this hypothesis by suggesting that anti-Ia serum plus C might remove from the responding cell population a cellular component of a non-MHC-antigen-activated suppressive mechanism, permitting unimpeded non-MHC-T_c generation in antigen-stimulated cultures (S. M. Macphail and F. H. Bach. Cytotoxicity and suppression induced by in vitro responses to non-H-2 histocompatibility antigens. Manuscript in preparation.). This interpretation is strengthened by two lines of experimental evidence. First, I-J-antigen-bearing suppressor T cells have been demonstrated in several systems (14, 15). Second, lymphocytes from non-MHC-antigen-primed donors produce an MLC proliferation-suppressing factor (16) and block the differentiation of MHC-specific memory T_c when these are restimulated with antigen in vitro (17). If this interpretation is correct, and we regard it as a likely mechanism, this would be the first demonstration of both suppressor cells in the cell-mediated immune response

(T_c) to non-MHC-antigens, and the existence of Ia-antigen-bearing, unprimed suppressor cells in vitro.

Other mechanisms by which anti-Ia serum and C may function cannot be ruled out. For instance, anti-Ia antibody may activate a dormant helper cell, or deliver a second requisite signal to a non-MHC-specific T_c precursor. Further experimentation should permit us to distinguish which of these possibilities is correct.

Summary

The results presented in this paper demonstrate that responding cells that remain after anti-Ia serum plus complement (C) treatment generate a highly significant in vitro cytotoxic response against minor histocompatibility complex antigens. The cytotoxic response appears to be antigen specific in that target cells of strains other than the sensitizing strain are not lysed, or lysed to a lesser extent. The cytotoxic cells are susceptible to anti-Thy-1 plus C lysis. Anti-Ia serum may function by removing an unprimed suppressor cell, although other mechanisms cannot be ruled out.

The authors wish to thank Dr. Kirsten Fisher-Lindahl, who offered insightful suggestions and comments at the initiation of this project, and Ms. Jean Holland, who skillfully drew the figures.

Received for publication 3 December 1979 and in revised form 7 February 1980.

References

1. Hildemann, W. H. 1970. Components and concepts of antigenic strength. *Transplant. Rev.* **3**:5.
2. Festenstein, H., J. A. Sachs, and R. F. D. Oliver. 1971. Genetic studies of the mixed lymphocyte reaction in H-2 identical mice. In *Immunogenetics of the H-2 System*. A. Lengerová and M. Vejtiskova, editors. S. Karger A Medical and Scientific Publishers, Basel.
3. Abassi, K., and H. Festenstein. 1973. Antigenic strength investigated by cell-mediated lympholysis in mice. *Eur. J. Immunol.* **3**:430.
4. Peck, A. B., and F. H. Bach. 1974. Mouse cell-mediated lympholysis assay in serum-free and mouse serum supplemented media: culture conditions and genetic factors. *Scand. J. Immunol.* **4**:53.
5. Rollinghoff, M., K. Pfizenmeir, H. Trostmann, and H. Wagner. 1975. T cell proliferation in the mixed lymphocyte culture does not necessarily result in the generation of cytotoxic effector cells. *Eur. J. Immunol.* **5**:560.
6. Bevan, M. J. 1975. The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. *J. Exp. Med.* **142**:1349.
7. Gordon, R. D., E. Simpson, and L. E. Samelson. 1975. In vitro cell-mediated immune responses to the male specific (H-Y) antigen in mice. *J. Exp. Med.* **142**:1108.
8. Peck, A. B., L. C. Anderson, and H. Wigzell. 1977. Secondary in vitro responses of T lymphocytes to non-H-2 alloantigens. Self-H-2-restricted responses induced in heterologous serum are not dependent on primary-stimulating non-H-2-alloantigens. *J. Exp. Med.* **145**:802.
9. Murphy, D. B., K. Okumura, L. A. Herzenberg, and H. O. McDevitt. 1976. Selective expression of separate I-region loci in functionally different lymphocyte subpopulations. *Cold Spring Harbor Symp. Quant. Biol.* **41**:497.
10. Hayes, C. E., and F. H. Bach. 1979. Murine T cell Ia antigens. II. Further studies on an I-J subregion specificity. *J. Immunol.* **123**:1678.

11. Mishell, R. I., and R. W. Dutton. 1967. Immunization of dissociated spleen cell cultures from normal mice. *J. Exp. Med.* **126**:423.
12. Hayes, C. E., and F. H. Bach. 1978. T-cell-specific murine Ia antigens: serology of *I-J* and *I-E* subregion specifications. *J. Exp. Med.* **148**:692.
13. Reif, A. E., and J. M. V. Allen. 1964. The AKR thymic antigen and its distribution in leukemias and nervous tissue. *J. Exp. Med.* **120**:413.
14. Murphy, D. B., L. A. Herzenberg, K. Okumura, L. A. Herzenberg, and H. O. McDevitt. 1976. A new I subregion (*I-J*) marked by a locus (*Ia-4*) controlling surface determinants on suppressor T lymphocytes. *J. Exp. Med.* **144**:699.
15. Greene, M. I., M. E. Dorf, M. Pierres, and B. Benacerraf. 1977. Reduction of syngeneic tumor growth by an anti-*I-J* alloantiserum. *Proc. Natl. Acad. Sci. U. S. A.* **74**:5118.
16. Kastner, D. I., R. R. Rich, L. Chu, and S. S. Rich. 1977. Regulatory mechanisms in cell-mediated immune responses V. H-2 homology requirements for the production of a minor locus-induced suppression factor. *J. Exp. Med.* **146**:1152.
17. Matossian-Rogers, A., and H. Festenstein. 1976. Modification of murine T-cell cytotoxicity by preimmunization with *M* locus and *H-2* incompatibilities. *J. Exp. Med.* **143**:456.